Abstract We thank Dr Davidson [1] for his interest in our paper,[2] which observed the non-
linear relationship between insulin doses resulting in smaller reductions in fasting plasma …

Insulin glargine clinical trials. - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …

Insulin glargine 300 U/ml in type 2 diabetes mellitus patients: results of the EDITION program
(review) | Shestakova | Problems of Endocrinology Problems of Endocrinology eng | рус User …

Study Objectives. To compare hemoglobin A1c (A1C) values at baseline with those after 1
year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' …

Abstract The Diabetes Control and Complications Trial (DCCT) demonstrated the
importance of optimal glycemic control achieved through intensive insulin therapy in …

Intervals of 10-30 min between oral insulin and meal ingestion were tried, but led to early
hypoglycaemia and (because of the short duration of action of oral insulin) to late …

OBJECTIVE: To review the pharmacology, pharmacokinetics, dosing guidelines, adverse
effects, drug interactions, and clinical efficacy of insulin glargine. DATA SOURCES: Primary …

I remember reading the note on the printed lab sheet that stated," The American Diabetes
Association recommends the goal of therapy to be A 1C results less than 7.0% and re …

This review discusses the role of basal insulin therapy in the treatment of patients with type 1
and type 2 diabetes in the light of the availability of a new long‐acting analogue, insulin …

Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on
continuous subcutaneous insulin infusion or once-nightly basal insulin Prandial therapy, for …